Spruce Biosciences, Inc.
SPRB
$0.0921
-$0.0377-29.05%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -51.32% | -1.40% | 131.82% | 415.63% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -51.32% | -1.40% | 131.82% | 415.63% | -- |
| Cost of Revenue | -6.10% | -23.55% | 1.26% | 25.09% | 40.44% |
| Gross Profit | -5.50% | 27.54% | 12.81% | -4.04% | -11.78% |
| SG&A Expenses | 15.76% | 10.11% | 12.51% | 9.81% | 4.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.64% | -16.29% | 3.81% | 21.38% | 31.30% |
| Operating Income | -8.00% | 18.32% | 6.58% | -5.50% | -9.96% |
| Income Before Tax | -10.68% | 19.72% | 10.49% | 0.96% | -3.77% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.68% | 19.72% | 10.49% | 0.96% | -3.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.68% | 19.72% | 10.49% | 0.96% | -3.77% |
| EBIT | -8.00% | 18.32% | 6.58% | -5.50% | -9.96% |
| EBITDA | -8.05% | 18.30% | 6.55% | -5.52% | -9.99% |
| EPS Basic | -1.48% | 35.75% | 37.08% | 38.46% | 35.56% |
| Normalized Basic EPS | -1.48% | 35.74% | 37.07% | 38.45% | 35.56% |
| EPS Diluted | -1.48% | 35.75% | 37.08% | 38.46% | 35.56% |
| Normalized Diluted EPS | -1.48% | 35.74% | 37.07% | 38.45% | 35.56% |
| Average Basic Shares Outstanding | 7.22% | 20.21% | 36.95% | 59.14% | 63.58% |
| Average Diluted Shares Outstanding | 7.22% | 20.21% | 36.95% | 59.14% | 63.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |